Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2 Billion
08 1월 2024 - 10:12PM
Dow Jones News
By Ben Glickman
Johnson & Johnson will acquire cancer-treatment developer
Ambrx Biopharma in a $2 billion cash deal.
The pharmaceutical giant said Monday that the deal to acquire
all shares of Ambrx for $28 each was expected have a value of $1.9
billion net of estimated cash required.
Ambrx said the deal represented a premium of 105% on the Jan. 5
closing price.
Ambryx is currently developing candidates for treatments for
multiple types of cancer, including for metastatic
castration-resistant prostate cancer, metastatic breast cancer and
renal cell carcinoma.
Johnson & Johnson said the deal presented an opportunity to
"design, develop and commercialize targeted oncology
therapeutics."
The acquisition is expected to close in the first half of the
year, subject to approval by Ambrx shareholders.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 08, 2024 07:57 ET (12:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Ambrx Biopharma (NASDAQ:AMAM)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Ambrx Biopharma (NASDAQ:AMAM)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
